NovoCure (NVCR) News Today → The Small Biotech with a BIG Cancer Solution (From Behind the Markets) (Ad) Free NVCR Stock Alerts $14.64 +1.57 (+12.01%) (As of 03/27/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNovoCure (NASDAQ:NVCR) Given New $24.00 Price Target at HC Wainwrightamericanbankingnews.com - March 28 at 4:52 AMNovoCure (NASDAQ:NVCR) Receives Neutral Rating from Wedbushamericanbankingnews.com - March 28 at 3:56 AMNovoCure: Sell The METIS-Inspired Rallyseekingalpha.com - March 27 at 10:55 PMNovoCure's (NVCR) Neutral Rating Reiterated at Wedbushmarketbeat.com - March 27 at 10:10 PMNuanced Phase 3 Results Prompt Cautious Hold Rating for NovoCure’s Stockmarkets.businessinsider.com - March 27 at 8:12 PMNovocure's device shown to slow cancer progression in the brain in trialmsn.com - March 27 at 8:12 PMPeeling Back The Layers: Exploring NovoCure Through Analyst Insightsmarkets.businessinsider.com - March 27 at 8:12 PMNovocure’s stock surges after positive results in brain-cancer trialmarketwatch.com - March 27 at 3:12 PMNovocure Shares Rise After Phase 3 METIS Trial Met Primary Endpointmarkets.businessinsider.com - March 27 at 3:12 PMNovocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Showsmsn.com - March 27 at 3:12 PMNovoCure (NASDAQ:NVCR) Price Target Raised to $24.00 at HC Wainwrightmarketbeat.com - March 27 at 2:13 PMNovoCure (NASDAQ:NVCR) Shares Gap Up to $13.07marketbeat.com - March 27 at 11:47 AMNovoCure device slows spread of lung cancer to brain in late-stage study; shares riseproactiveinvestors.com - March 27 at 11:00 AMNovocure Shares Surge Premarket on Phase 3 TTFields Studymarketwatch.com - March 27 at 10:11 AMNovocure shares jump after trial meets primary endpointinvesting.com - March 27 at 10:11 AMNovocure's lung cancer therapy succeeds in late-stage trialmsn.com - March 27 at 10:11 AMmarketbeat.com - March 27 at 9:41 AMZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancerbusinesswire.com - March 27 at 9:29 AMMETIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancerbusinesswire.com - March 27 at 7:00 AMNovoCure (NASDAQ:NVCR) Stock Price Down 6%americanbankingnews.com - March 24 at 6:20 AMNovoCure (NASDAQ:NVCR) Trading Down 6%marketbeat.com - March 22 at 5:06 PMJPMorgan Chase & Co. Raises NovoCure (NASDAQ:NVCR) Price Target to $17.00americanbankingnews.com - March 21 at 2:28 AMNovoCure (NASDAQ:NVCR) Price Target Raised to $17.00marketbeat.com - March 20 at 10:39 AMNVCR Dec 2025 17.500 callfinance.yahoo.com - March 20 at 5:21 AMNVCR Jan 2026 20.000 callfinance.yahoo.com - March 20 at 5:21 AMNVCR Apr 2024 10.000 putfinance.yahoo.com - March 15 at 8:59 PMNVCR Apr 2024 17.500 callfinance.yahoo.com - March 15 at 8:59 PMNovoCure’s Clinical Trial Results: Subgroup Promise Amidst Cautioned Market Outlookmarkets.businessinsider.com - March 12 at 8:11 PMNovoCure (NASDAQ:NVCR) Shares Down 3.9% marketbeat.com - March 12 at 12:53 PMINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGObusinesswire.com - March 11 at 7:00 AMNovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of "Moderate Buy" from Analystsmarketbeat.com - March 11 at 2:32 AMSeven Eight Capital LP Acquires 71,989 Shares of NovoCure Limited (NASDAQ:NVCR)marketbeat.com - March 6 at 9:50 AMFederated Hermes Inc. Makes New $1.10 Million Investment in NovoCure Limited (NASDAQ:NVCR)marketbeat.com - March 5 at 7:22 AMPalo Alto Investors LP Purchases 82,157 Shares of NovoCure Limited (NASDAQ:NVCR)marketbeat.com - March 1 at 10:27 AMIs NovoCure Limited (NASDAQ:NVCR) Worth US$16.0 Based On Its Intrinsic Value?finance.yahoo.com - February 29 at 10:26 AMNovoCure (NASDAQ:NVCR) Shares Up 6.7%marketbeat.com - February 27 at 12:31 PMBuy Rating Affirmed for NovoCure Amid Strong Q4 Performance and Promising Pipeline Developmentsmarkets.businessinsider.com - February 26 at 8:20 AMConnor Clark & Lunn Investment Management Ltd. Acquires 339,610 Shares of NovoCure Limited (NASDAQ:NVCR)marketbeat.com - February 26 at 8:18 AMBuy Rating Affirmed for NovoCure Amid Positive Clinical Results and Solid Financial Performancemarkets.businessinsider.com - February 24 at 1:18 PMNovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 23 at 3:14 PMNovoCure (NASDAQ:NVCR) Posts Earnings Results, Beats Estimates By $0.08 EPSmarketbeat.com - February 23 at 3:10 PMNovoCure Limited (NASDAQ:NVCR) to Post FY2028 Earnings of ($1.01) Per Share, HC Wainwright Forecastsmarketbeat.com - February 23 at 8:22 AMNovoCure Stock (NASDAQ:NVCR), Short Interest Reportbenzinga.com - February 23 at 5:12 AMNovoCure Limited (NASDAQ:NVCR) Holdings Cut by Barclays PLCmarketbeat.com - February 23 at 4:17 AMNovoCure Ltd (NVCR) Reports Mixed Financial Results for Q4 and Full Year 2023finance.yahoo.com - February 22 at 12:40 PMNovoCure (NVCR) Q4 2023 Earnings Call Transcriptfool.com - February 22 at 12:40 PMmarketbeat.com - February 22 at 9:35 AMNovoCure Limited 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - February 22 at 8:18 AMNovoCure: Q4 Earnings Snapshotwashingtonpost.com - February 22 at 7:39 AMNovoCure GAAP EPS of -$0.45 beats by $0.07, revenue of $133.78M in-linemsn.com - February 22 at 7:39 AM Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies. Find out how you can protect yourself now >>> NVCR Media Mentions By Week NVCR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCR News Sentiment▼0.180.61▲Average Medical News Sentiment NVCR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCR Articles This Week▼215▲NVCR Articles Average Week Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LeMaitre Vascular News AtriCure News MiMedx Group News Alphatec News Tandem Diabetes Care News Artivion News Paragon 28 News Atrion News Treace Medical Concepts News Embecta News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVCR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.